Buoyed by promising results of a Phase I study demonstrating the safety of mesenchymal stem cell therapy to treat frailty in older adults, researchers at the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine have taken it a step further.
Now Phase II randomized, placebo-controlled trial findings have verified their initial study, boosting the potential for this stem cell therapy to reverse or forestall the symptoms of frailty. Not only is there no currently approved medical therapy for frailty, the need is expected to grow substantially given the overall aging of the U.S. population.
“It’s a huge need — that’s one of the exciting things,” said Joshua M. Hare, M.D., the Louis Lemberg Professor of Medicine and founding director of ISCI. Frailty is estimated to affect about 10 to 11 percent of seniors, a considerable percentage of the 50 million people older than 65 years experts predict by the year 2050.
Results of the AllogeneiC Human Mesenchymal Stem Cell in Patients with Aging FRailTy via IntravenoUS Delivery (CRATUS) Phase I trial and subsequent CRATUS Phase II trial were simultaneously published online October 12 in The Journals of Gerontology. In an accompanying guest editorial, David G. Le Couter, M.D., Ph.D., professor of medicine at the University of Sydney, and colleagues praised the work.
“These trials represent potential landmarks in the treatment of frailty,” they wrote. “Both studies are early-phase trials of a small number of participants, designed primarily to assess safety, so conclusions about efficacy need to be treated with caution. Even so, the results are striking and, at minimum, pave the way for large randomized Phase III clinical trials.”
“I was very surprised and excited with the results,” Hare said. Replicating their results in the Phase II randomized trials “gives me even greater confidence” in the findings. For example, both trials demonstrated a significant and meaningful increase in six-minute walk tests among older adults with frailty compared to their baseline.
“The idea that we can biologically modify frailty is very exciting,” Hare said. In fact, the research by Hare and his team demonstrate the beneficial effects of mesenchymal stem cell therapy in this population, including their anti-inflammatory effects, pro-regenerative capabilities, and anti-fibrotic actions (meaning they can decrease scar tissue). The investigators have also shown the therapy promotes new vessel growth and improves endothelial function.
“Mesenchymal stem cells are a multifactorial way of offsetting many of the key features of aging,” Hare said.
Learn more: Stem Cell Studies Build Momentum toward Therapy for Age-Associated Frailty
The Latest on: Mesenchymal stem cell therapy
[google_news title=”” keyword=”Mesenchymal stem cell therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- In What Way Can Regenerative Medicine Help Patients Suffering From Ankylosing Spondylitis?on May 16, 2024 at 1:31 pm
"Therapy based on the use of mesenchymal stem cells, which is regenerative, not only provides symptom relief, but also slows the progress of the disease, thereby giving hope to AS patients," the ...
- Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseaseson May 16, 2024 at 6:52 am
OTCPK:TSOI) Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases ...
- Technology Insight: Adult Mesenchymal Stem Cells for Osteoarthritis Therapyon May 14, 2024 at 5:00 pm
Targeted gene therapy might further enhance these activities ... for OA are inadequate Delivery of an appropriate mesenchymal stem cell (MSC) population is currently being investigated in the ...
- Therapeutic potential of human umbilical cord-derived mesenchymal stem cells in Crohn’s diseaseon April 24, 2024 at 5:00 pm
researchers investigated whether human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) could heal luminal ulcers in Crohn’s disease (CD) patients. Study: hUC-MSCs therapy for Crohn’s ...
- The murky, unregulated world of anti-ageing stem cell therapyon April 24, 2024 at 11:52 am
Prof Frampton describes the therapy as a complex multi-stage process in which surgeons extract the patient’s own mesenchymal stem cells before using them to generate new ligament or cartilage ...
- Instructing iPS cell-derived mesenchymal stem cells to inhibit abnormal bone formation in FOPon March 27, 2024 at 2:02 pm
Their report is published in Stem Cell Research & Therapy. FOP is a rare autosomal-dominant genetic disorder characterized by congenital bone malformation and progressive extraskeletal ...
- Mesenchymal Stem Cells News and Researchon March 13, 2024 at 5:01 pm
Researchers unveiled a novel therapy for diabetic wound healing. This research highlights the use of exosomal miR-4645-5p from hypoxic bone marrow mesenchymal stem cells (BMSCs) to significantly ...
- Traveling for Treatment: Stem Cell Therapy Abroadon May 17, 2023 at 11:04 pm
How exactly does stem cell therapy work? BioXcellerator uses the mesenchymal stem cells derived from the Wharton jelly of the umbilical cord. This helps them avoid the ethical controversies that ...
- Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell nicheon May 29, 2021 at 5:13 am
Cell therapy could lead to successful cardiac ... In a porcine model of myocardial infarction, allogeneic mesenchymal stem cells stimulated substantial improvement in the ejection fraction ...
- Brainstorm Stem-Cell Therapy Continues to Show Treatment Effect in ALS Patientson January 5, 2015 at 7:52 am
The company's experimental NurOwn stem-cell therapy starts with the harvesting of bone marrow from each ALS patient. Mesenchymal stem cells are isolated from the bone marrow sample and sent to a ...
via Google News and Bing News